CN115768419A - 用于色满卡林前药治疗的改进方法和组合物 - Google Patents

用于色满卡林前药治疗的改进方法和组合物 Download PDF

Info

Publication number
CN115768419A
CN115768419A CN202180024624.5A CN202180024624A CN115768419A CN 115768419 A CN115768419 A CN 115768419A CN 202180024624 A CN202180024624 A CN 202180024624A CN 115768419 A CN115768419 A CN 115768419A
Authority
CN
China
Prior art keywords
formula
pharmaceutically acceptable
cklp1
compound
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024624.5A
Other languages
English (en)
Chinese (zh)
Inventor
T·M·胡托
B·M·维罗斯特科
M·P·福特施
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quelaris Biology
Mayo Clinic in Florida
Original Assignee
Quelaris Biology
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quelaris Biology, Mayo Clinic in Florida filed Critical Quelaris Biology
Publication of CN115768419A publication Critical patent/CN115768419A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN202180024624.5A 2020-02-07 2021-02-05 用于色满卡林前药治疗的改进方法和组合物 Pending CN115768419A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062971752P 2020-02-07 2020-02-07
US62/971,752 2020-02-07
US202063120604P 2020-12-02 2020-12-02
US63/120,604 2020-12-02
US202163134042P 2021-01-05 2021-01-05
US63/134,042 2021-01-05
PCT/US2021/016920 WO2021158992A1 (en) 2020-02-07 2021-02-05 Improved methods and compositions for cromakalim prodrug therapy

Publications (1)

Publication Number Publication Date
CN115768419A true CN115768419A (zh) 2023-03-07

Family

ID=77199473

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024624.5A Pending CN115768419A (zh) 2020-02-07 2021-02-05 用于色满卡林前药治疗的改进方法和组合物

Country Status (7)

Country Link
US (1) US20220387457A1 (https=)
EP (1) EP4100003A4 (https=)
JP (1) JP2023512828A (https=)
CN (1) CN115768419A (https=)
AU (1) AU2021215932A1 (https=)
CA (1) CA3166579A1 (https=)
WO (1) WO2021158992A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981951B2 (en) * 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma
CA3159771A1 (en) 2019-12-12 2021-06-17 Thurein M. Htoo Controlled-delivery cromakalim prodrugs
EP4384162A4 (en) * 2021-08-12 2025-06-04 Qlaris Bio, Inc. Compositions and methods for extended-release bromo-kallim therapy
CN115058440B (zh) * 2022-06-08 2023-08-15 郑州轻工业大学 催化合成天然蔗糖酯的工程菌及其构建方法和应用
GB202211936D0 (en) * 2022-08-16 2022-09-28 Royal Veterinary College Method and treatment for diabetes
IL320428A (en) * 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
CN119548509B (zh) * 2024-11-21 2025-11-14 中山大学中山眼科中心 一种小分子化合物组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170002040A1 (en) * 2014-01-31 2017-01-05 Mayo Foundation For Medical Education And Research Novel therapeutics for the treatment of glaucoma
CN109906104A (zh) * 2016-09-08 2019-06-18 瑞吉纳拉制药公司 包括三萜类的组合物及其用于治疗视神经病变的用途
CN115443132A (zh) * 2019-12-12 2022-12-06 奎拉里斯生物公司 色满卡林前药的受控递送

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308062D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
WO1989010757A1 (en) * 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis New ophthalmic preparation for treating glaucoma
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
DK2838533T3 (da) * 2012-04-16 2017-11-27 Univ Case Western Reserve Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet
MA41252A (fr) * 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170002040A1 (en) * 2014-01-31 2017-01-05 Mayo Foundation For Medical Education And Research Novel therapeutics for the treatment of glaucoma
CN109906104A (zh) * 2016-09-08 2019-06-18 瑞吉纳拉制药公司 包括三萜类的组合物及其用于治疗视神经病变的用途
CN115443132A (zh) * 2019-12-12 2022-12-06 奎拉里斯生物公司 色满卡林前药的受控递送

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MICHAEL P FAUTSCH等: "Pharmacologic and safety profile of the ocular hypotensive agent cromakalim prodrug 1 (CKLP1), a novel ATP-sensitive potassium channel opener", 《ARVO ANNUAL MEETING ABSTRACT》, vol. 60, no. 9, 31 July 2019 (2019-07-31) *
UTTIO ROY CHOWDHURY等: "Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity", 《J MED CHEM.》, vol. 59, no. 13, 14 July 2016 (2016-07-14), pages 6221 - 6231, XP055383186, DOI: 10.1021/acs.jmedchem.6b00406 *
UTTIO ROY CHOWDHURY等: "Effect of Cromakalim Prodrug 1 (CKLP1) on Aqueous Humor Dynamics and Feasibility of Combination Therapy With Existing Ocular Hypotensive Agents", 《OPHTHALMOL VIS SCI》, vol. 58, 1 November 2017 (2017-11-01), pages 5731 - 5742 *
UTTIO ROY CHOWDHURY等: "Ocular hypotensive properties of water soluble prodrugs of the ATP sensitive potassium channel opener cromakalim", 《ARVO ANNUAL MEETING ABSTRACT》, vol. 57, 30 September 2016 (2016-09-30) *
庄曾渊等主编: "《庄曾渊实用中医眼科学》", vol. 1, 29 February 2016, 中国中医药出版社, pages: 421 - 424 *
马晓萍等主编: "《眼科微缩指南——365天 日进一智》", vol. 1, 31 March 2014, 复旦大学出版社, pages: 300 *

Also Published As

Publication number Publication date
WO2021158992A1 (en) 2021-08-12
CA3166579A1 (en) 2021-08-12
US20220387457A1 (en) 2022-12-08
AU2021215932A1 (en) 2022-09-15
JP2023512828A (ja) 2023-03-29
EP4100003A1 (en) 2022-12-14
EP4100003A4 (en) 2024-04-24

Similar Documents

Publication Publication Date Title
US20220387457A1 (en) Methods and compositions for cromakalim prodrug therapy
EP1802373B1 (en) Carboxy-amido-triazoles for the localized teatment of ocular diseases
US12454539B2 (en) Controlled-delivery cromakalim prodrugs
US20020193376A1 (en) Method for treating glaucoma V
EA024042B1 (ru) Способ снижения внутриглазного давления у людей
IL126836A (en) Beta-inhibitor of protein kinase C beta-use for use as a drug for the treatment of eye diseases
JP2024532015A (ja) 徐放性クロマカリム療法用の組成物及び方法
EP3416654B1 (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
US9629826B2 (en) CAI-based systems and methods for the localized treatment of uveitis
EP3733179A1 (en) Pharmaceutical preparation containing pyridyl aminoacetic acid compound
US20190275022A1 (en) Methods, compositions, and compounds for treatment of dermatological and ocular conditions
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
WO2022259133A1 (en) Trpa1 channel antagonist compound for use in degenerative retinal diseases
HK40073052A (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
HK1263210B (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
Gunda Ocular pharmacokinetics and efficacy of various amino acid and dipeptide prodrugs of ganciclovir
WO2016061378A1 (en) Cai-based systems and methods for the localized treatment of uveitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230307

WD01 Invention patent application deemed withdrawn after publication